Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q99619

UPID:
SPSB2_HUMAN

ALTERNATIVE NAMES:
Gene-rich cluster protein C9

ALTERNATIVE UPACC:
Q99619; B7Z4W1; D3DUT0

BACKGROUND:
SPRY domain-containing SOCS box protein 2, identified as Gene-rich cluster protein C9, is integral to the ECS E3 ubiquitin-protein ligase complex, mediating ubiquitination and subsequent degradation of proteins. It plays a pivotal role in controlling nitric oxide levels by targeting NOS2 for degradation in macrophages, thus regulating cellular responses to inflammation and limiting damage.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of SPRY domain-containing SOCS box protein 2 offers a promising pathway for therapeutic intervention. Its critical role in modulating nitric oxide production and cellular toxicity in immune responses positions it as a potential target for drug development, particularly in treating diseases characterized by excessive inflammation or nitric oxide production.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.